Keros Therapeutics’ (KROS) “Buy” Rating Reiterated at HC Wainwright

Keros Therapeutics (NASDAQ:KROS)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $40.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 298.41% from the stock’s previous close.

KROS has been the subject of a number of other research reports. TD Cowen lowered Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Wells Fargo & Company cut their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. BTIG Research downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Scotiabank cut their target price on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research note on Thursday, January 16th. Finally, Guggenheim reiterated a “neutral” rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Keros Therapeutics has an average rating of “Moderate Buy” and an average price target of $42.33.

Keros Therapeutics Trading Up 5.1 %

NASDAQ KROS opened at $10.04 on Tuesday. Keros Therapeutics has a 12 month low of $9.41 and a 12 month high of $72.37. The stock has a market cap of $407.24 million, a price-to-earnings ratio of -1.93 and a beta of 1.39. The company’s 50 day moving average is $11.07 and its two-hundred day moving average is $33.47.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.36) by $0.22. The firm had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Sell-side analysts forecast that Keros Therapeutics will post -4.74 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Braidwell LP increased its stake in Keros Therapeutics by 167.9% during the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company’s stock worth $29,989,000 after acquiring an additional 1,187,199 shares during the last quarter. Point72 Asset Management L.P. increased its position in shares of Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after purchasing an additional 577,220 shares during the last quarter. Lynx1 Capital Management LP purchased a new stake in Keros Therapeutics during the 4th quarter valued at $8,612,000. Millennium Management LLC lifted its position in Keros Therapeutics by 53.3% in the fourth quarter. Millennium Management LLC now owns 878,159 shares of the company’s stock worth $13,901,000 after buying an additional 305,169 shares during the last quarter. Finally, Boxer Capital Management LLC purchased a new position in Keros Therapeutics during the fourth quarter worth $3,958,000. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.